The US Food and Drug Administration (FDA) has mandated that manufacturers of GLP-1 medications, a class of drugs frequently prescribed for weight loss, add new warnings to their labels regarding a rare eye condition. The federal agency announced on Monday that these drugs must now include information about the potential risk of nonarteritic anterior ischemic optic neuropathy (NAION), a condition that can lead to sudden and permanent blindness.

This directive applies to several widely recognised GLP-1 medications, including Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound, and Sanofi's Soliqua. The updated labelling aims to inform both patients and healthcare providers about this serious, albeit rare, ocular adverse event.

NAION is characterised by a sudden loss of vision in one eye due to insufficient blood flow to the optic nerve. While rare, the potential for permanent visual impairment underscores the FDA's decision to enforce these new warnings across the entire GLP-1 drug class.

The FDA's action follows an extensive analysis of clinical trial data. The agency reviewed 126 clinical trials involving a total of 134,253 participants. This comprehensive review revealed a higher incidence of NAION among individuals using GLP-1 drugs compared to those administered placebos or other medications typically used for diabetes treatment. This statistical finding provided the basis for the federal agency's requirement for updated safety information.

GLP-1 receptor agonists have gained significant prominence in recent years due to their efficacy in facilitating weight loss, in addition to their established role in managing type 2 diabetes. As their use continues to expand globally, the FDA's move highlights an ongoing commitment to patient safety through transparent and comprehensive drug labelling. The updated warnings ensure that users are fully aware of all potential risks associated with these powerful medications.